The understanding, investigation and management of cystic fibrosis (CF), one of the commonest autosomal recessive inherited disorders in the Western world, have undergone dramatic changes over the last 30 years. Contributing to these changes were the major discoveries in the 1980s of the underlying chloride and other electrolyte transport defects in epithelial tissue 1, 2 and the discovery of the 'CF gene', the CF transmembrane conductance regulator gene (CFTR). 3, 4 CFTR protein was later proven to be the cAMP-stimulated chloride channel in epithelial tissue, 5 with mutations leading to production of defective CFTR protein and significantly impaired chloride transport. These discoveries have vastly improved our knowledge of the pathophysiology of this disorder and form the basis of the intensive research effort over the last two decades to improve CFTR function, which has now been achieved for at least one specific mutation, but may also be applicable to others.
Over the same time frame, survival for CF patients has markedly improved. In the 1950s and early 1960s for example, the majority of children diagnosed with CF before the age of 10 years were usually dead from lung disease by this age. 6 By the early 1980s Corey 7 from the Toronto clinic reported a median survival of B30 years, and most recently a further improvement has been reported, of over 45 years, in the Toronto and other Canadian clinics. 8 Part of this improvement can be attributed to the early and intensive antibiotic regimens, physical and drug lung clearance techniques, delivery of care through specialist CF clinics 9 and early diagnosis, particularly related to neonatal screening. 10 Moreover, a significant nutritional role was also evident in the early 1980s, with a 10-year better survival at the Toronto clinic, whose patients had achieved nearnormal growth and nutritional status compared to others worldwide.
The current review will focus on factors interfering with nutrient balance with subsequent undernutrition and growth failure and an approach to correct or prevent nutrient deficits to maintain optimal growth in CF patients.
NUTRITION AND SURVIVAL IN CF
Through the 1960s and 1970s, growth failure among CF populations was common, 11 as depicted in Figure 1 . Patients were in general underweight at diagnosis, improving with therapy but still remaining on average À 1 s.d. score below the median during mid-childhood and declining further through adolescence. The growth failure observed was attributed to the underlying disease, early-onset lung disease and poor control of malabsorption.
In addressing the latter, the oral pancreatic enzyme replacement therapy (PERT) then used consisted of porcine pancreatic extract presented in a powder form for infants and young children or gelatine capsule packaged powder for older children and adults. However, these preparations were suboptimal, as the pancreatic enzyme powder released into the stomach was inactivated by gastric acid/pepsin digestion. 12 Fat balance studies demonstrated that patients not receiving PERT had average faecal fat excretions of 40% of oral fat intake 13 and when receiving PERT 25-30%, 12 indicating only a mild improvement. Two strategies were adopted in the 1960s and 1970s in order to circumvent the minimal efficacy of PERT, namely the institution of low-fat diets to decrease the degree of steatorrhoea and the use of medium-chain triglyceride (MCT) diets, as CF infant studies showed normal fat excretion on MCT-based formulae 14 without PERT supplementation. However, with hindsight, both of these strategies were flawed. Low-fat diets provided energy intakes of 80-90% of the recommended dietary intake (RDI) 15, 16 and thus were clearly inadequate, providing suboptimal intakes for even a normal child, let alone a CF child with increased needs due to malabsorption and lung disease. Not surprisingly, chronic undernutrition and growth failure ensued, similar to the effects of chronic starvation seen in the Third World. Weight and linear growth failure were also seen in those receiving MCT formulae without PERT supplementation. Scrutiny of the original studies revealed that the Van de Kamer method for measuring long-chain triglyceride was used to assess faecal fat excretion, and thus in the MCT-fed group fat excretion was seriously underestimated. Later, a study using the correct method for measuring faecal MCT demonstrated that average fat excretion on MCT without PERT was 26%, improving to o10% on PERT. 17 The eventual outcome of the cohort of CF infants fed the MCT formula without PERT was growth failure. 11, 18 As alluded to in the above introduction, the Toronto clinic had achieved near-normal linear growth and weight, particularly in their male patients extending into older childhood. A summary of these data is shown in Table 1 in comparison with data from a CF clinic in Sydney with a low-fat dietary regimen. 15 While in both clinics females X8 years had a higher proportion than males below the third percentile for weight, between the two clinics, Sydney had 42% of females versus 16% in Toronto (33% versus 8% of males, respectively) below the third percentile, emphasising the more marked degree of wasting in the Sydney clinic and in females in both clinics. Clearly, the Toronto clinic had outperformed the Sydney clinic and, as others noted, also other North American clinics, 7 and the question arose as to how the difference was achieved.
Bell et al. 19 revealed that the Toronto clinic had not adhered to the 'low-fat diet policy'. They had instead recommended a diet with over 40% of the energy as long-chain triglyceride (based on the principle that if fat excretion as a percentage of fat intake remained relatively constant, increasing the absolute fat intake would ensure a greater amount of absolute fat assimilated), and were able to demonstrate in their report an average energy intake of 113% RDI, that is, well in excess of patients' energy consumption on low-fat diets of between 80-90% RDI. In addition, a specific review emphasised the importance of the 'high'-versus 'low'-fat diet in explaining the difference in growth and perhaps survival between the Toronto and other clinics in an era when PERT was suboptimal. 20 Although the above studies appeared to be authoritative, involving large-cohort analyses, they were, however, in the most retrospective and required confirmation. Key issues surrounded whether simple changes in dietary regimen used would lead to correction and/or prevention of subsequent malnutrition, or were specific feeding regimens, for example, overnight gastrostomy regimens, required to reverse severe malnutrition and growth failure, with restoration of normal growth. Simple reversal of diets from a low-to high-fat regimen was shown to improve growth over a 12-month period, 16, 21 with a similar finding in later invasive feeding studies with total pareneteral nutrition, gastrostomy or jejunal feeds. [22] [23] [24] However, the latter were short term and reports of improved lung function or slowing decline of lung function were premature, as the studies were not powered to assess this effect. Long-term gastrostomy feeds could restore normal growth and nutrition to severely malnourished, stunted and wasted patients 25 (cf Figure 2 ), indicating that their growth failure was likely nutritional in origin and unrelated to the basic disease.
To assess the effect of nutrition on survival, a direct comparison of cohorts from the Toronto and Boston clinics who had similar respiratory treatments but used high-and low-fat regimens, respectively, demonstrated a near-10-year survival advantage for the Toronto patients, but notably, virtually identical spirometric lung function results at 20 years of age. 26 In addition, at the Sydney clinic, a high-fat diet and a microspheric PERT were introduced in the early 1980s. A subsequent analysis of this population in 1994 involving children X8 years showed that only 9% of males and 2% of females were below the third percentile for weight and over 30% were above the 50th percentile. 27 Stunting was unusual, with 13% and 5% of males and females, respectively, below the 3rd percentile and B40% of both genders above the 50th percentile. A further cohort study at the Sydney clinic compared pulmonary function at 10 10 and 15 years 28 post screening diagnosis in infants born in the 3 years prior to the commencement of screening with those born in the first 3 years of screening, and demonstrated a 10% advantage in the percent predicted FEV 1 (forced expiratory volume) at both times in the screened infants, a 16% advantage at 18 years and significantly better survival at 25 years. 29 Clearly there are advantages to early diagnosis and treatment as emphasised by the large US CF Foundation database study demonstrating the longer survival and maintenance of lung function in those diagnosed and treated from an early age, as also emphasised by Canadian data demonstrating median survivals now reaching the 45-50-year-old age range. 8 Maintenance of normal nutrition appears to be one contributing factor, but whether it helps to maintain survival throughout adult life is unknown. 
ORIGIN OF NUTRITIONAL PROBLEMS IN CF
The nutritional complications of CF patients generally relate to nutrient imbalance, as nutrient intake for normal function and growth is inadequate to balance losses due to maldigestion/ malabsorption or excessive utilisation. Figure 3 depicts the multiple factors involved in the generation of malnutrition within four major areas, including inadequate intake, maldigestion/ malabsorption, excessive energy expenditure, and the gene defect itself.
Macronutrient intake
In macronutrient balance studies on high-fat regimens given orally, protein and energy intakes have averaged 200% 15 and 113% RDI, respectively. 19 In addition, reasonably high protein intakes averaging 170% RDI have been observed in patients on low-fat diets, but energy intakes were suboptimal, averaging less than 90% RDI and associated with poor linear growth. 15, 16, 21 Limited data are available to assess how varying protein and energy intakes influence protein deposition in either normal children/adolescents or CF patients. On using cross-sectional data in normal prepubertal children 4-11 years of age, total body nitrogen measured by in vivo prompt gamma neutron capture analysis increased at the rate of 100 g/year, 30 a figure that increased during puberty to between 130-150 g/year. 31 During enteral (gastrostomy) and oral feeding regimens for malnourished CF patients and calculation of nitrogen deposition rates from at least two and up to four measurements performed over the study interval, nitrogen deposition rates varied from À 230 (that is, negative balance with loss of N) to over 500 g/year (that is, positive balance with gain of N), with only three patients in negative balance throughout the entire study. 32 These studies indicate that it is possible to achieve normal nitrogen deposition, and positive energy balance and weight and height growth with adequate intake, given the obvious exceptions of those who were non-compliant to the regimen.
Macronutrient malabsorption Over 85% of CF patients have pancreatic insufficiency (PI) with associated fat maldigestion and subsequent malabsorption over 7% of the oral fat intake. 33 The remaining patients are pancreatic sufficient (PS), indicating that they have sufficient endogenous pancreatic enzyme secretion to maintain a normal faecal fat excretion, that is, p7% of the oral fat intake. These definitions are based on quantitative pancreatic stimulation tests with duodenal aspiration of pancreatic juice, and analysis of lipase and the lipase co-factor, colipase, in comparison with faecal fat excretion during 3-5-day fat balance studies. 34, 35 Colipase determines the amount of lipase activity in the presence of bile acids, 34 and thus it was not unexpected that the amount of colipase secreted was a critical factor in these studies, as patients secreting over 1% of average normal colipase had normal fat absorption and o1% fat malabsorption, as per Figure 4 . 35 Genotyping as per classes of CFTR mutations 36 of patients with PI and PS pancreatic phenotypes has revealed that PI patients have two type I, II or III mutations and PS patients at least one type IV or V mutation. PS is associated with not only a milder pancreatic disease, but in general a milder lung disease, normal growth and better survival. 33 Meconium ileus and cirrhosis of the liver with portal hypertension are unusual occurrences. 33 Of importance, at neonatal screening diagnosis up to 40% of CF infants are PS, 37 but over the first 10 years of life over half of those originally PS become PI and the latter to date have carried two type I to III mutations, which are associated with severe pancreatic disease. 38, 39 Three-to five-day balance studies in PI patients have shown that fat malabsorption may vary from over 7% of fat intake to B80%, with an average near 40%. 13 Nitrogen balance studies demonstrate losses varying up to 50% of nitrogen intake. 40 Considering these large losses, it is not surprising that using the pre-1980s PERT, which had minimal effect on the degree of malabsorption, patients developed malnutrition and poor growth. The newer microspheric PERT preparations have been developed to circumvent the problem with acid pepsin digestion of the previous powder form of enzymes. Currently, with the use of capsules containing 5000 IU of lipase at a dose of 1 capsule/kg/day (up to 30-40 capsules maximum) divided between meals and snacks, average fat excretions in various studies have varied between 10-15% of fat intake, that is, a marked improvement compared with the pre-microspheric PERT preparations. [41] [42] [43] In addition to growth failure, untreated PI is also associated with severe hypoproteinaemia. Classically, in infancy this occurs in regions without neonatal screening, and particularly in breast-fed infants with lower protein intakes than formula-fed infants. With the advent of neonatal screening and therefore early diagnosis of PI, microspheric PERT is commenced early in life and this complication is avoided, ensuring also that even if exclusive breast feeding continues for 6 to 12 months, by 2 years of age these infants have achieved and maintained normal growth. 44 Increased energy expenditure Feigil and Shapiro 45 demonstrated a doubling of O 2 consumption in cultured CF fibroblasts in 1979, a finding confirmed by others. 46 Soon thereafter, several studies demonstrated increased resting energy expenditure (REE) in CF patients and postulated that this was related to the severity of lung disease and/or malnutrition. [47] [48] [49] In a CF infant study measuring total energy expenditure (TEE) by the doubly labelled water technique, TEE was increased to B25% above controls. 50 The investigators suggested that in the absence of severe lung disease at this early age the increased TEE was related to the underlying gene defect. Other studies supported these findings, 51 but Fried et al 52 contended that their retrospective data indicated it was related to deteriorating lung function.
In a large study of 104 CF patients with near-normal lung function (FEV 1 averaging over 80%) PI patients were shown to have a significant increase in REE of 110% of that seen in PS patients. 53 Given the latter is genetically determined, the results suggest there is a significant genetic component to the higher REE in PI patients. This study also assessed whether there were gender differences and demonstrated that whereas CF males maintained a mild increase of REE of 104% of control values, CF females demonstrated a highly significant increase of 111% in comparison with female controls. These findings were confirmed in a further longitudinal study where post-pubertal females averaged over 116% of the REE of control values. 54 These findings to date are unexplained, 55 but as others have commented, they could help to explain the CF females' disadvantage in terms of survival. 56 Micronutrient deficiencies Fat-soluble vitamins-A, D, E and K. Deficiencies of fat-soluble vitamins have been well documented in PI patients at any age, but have usually occurred in infancy in regions without newborn screening, or in the era of pre-microspheric enzymes and more recently in patients non-compliant to microspheric PERT and/or vitamin supplementation.
In non-screened areas, infants may present with raised intracranial pressure 57 and distended fontanelle as a manifestation of vitamin A deficiency. However, in older patients, night blindness is associated with serum A levels o0.5 mmol/l and the symptom readily alerts carers to the likely problem. 58 Overt rickets and osteomalacia due to vitamin D deficiency, although unusual, do occur in northern hemisphere countries with prolonged winters and lack of sun exposure. [59] [60] [61] Probably much more common are subclinical or biochemical rickets where 25-OH-D levels decline below the lower limit of normal of 50 nmol/l. In hotter countries, the same phenomenon can occur, as parents and children are now advised against prolonged sun exposure and thus regular vitamin D supplements are required for those so affected. Vitamin E deficiency with overt features of neuropathy, ataxia and external ophthalmoplegia is very rare in the modern era of CF management. [62] [63] [64] Supplementation with vitamin E 25 IU/kg/day in most patients maintains serum E levels above 7 mg/ml, and this appears sufficient for the prevention of neuropathology seen with vitamin E deficiency. Monitoring of A and E levels in PS patients is of value, as the occurrence of low levels could suggest the patient has become PI. 65 Finally, vitamin K deficiency with coagulopathy is again a rare occurrence 66, 67 in the modern era, but coagulation status should be monitored in infants, particularly with cholestasis, or in those with ongoing steatorrhoea in spite of adequate PERT. Table 2 ) reflect the requirements of PI patients. PS patients thrive on normal diets, with the only exception that they require similar salt intakes to their PI counterparts, as they also are at risk of excessive sweat salt losses. Decline in growth rates, hypoproteinaemia, and decline of fat-soluble vitamin and other micronutrient levels indicate undernutrition and require counselling and correction of the deficits. Although most of the nutritional deficiencies can be corrected orally, the occurrence of severe chest disease, decline in lung function, oesophagitis, biliary tract and intestinal disease can be accompanied by anorexia, interfering with oral intake. Persistence of anorexia after appropriate therapy of confounding complications, for example, lung disease, may well necessitate the patient having tube feeding for short or prolonged intervals. [22] [23] [24] 68, 69 Continuing invasive nutrition will be required if weight decline over a 6-month interval is below the 3rd percentile and, similarly, if body mass index drops below the 10th percentile. However, the benefit of providing invasive nutrition besides improving the patient's nutritional status and growth is questionable in terms of survival and lung function. It would appear appropriate for patients awaiting lung transplantation to provide optimal nutrition, but this remains to be proven with prospective studies.
